Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonmyeloablative hematopoietic cell transplantation.

L Feinstein1, R Storb

  • 1Program in Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.

Current Opinion in Oncology
|February 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Persistent socioeconomic and racial and ethnic disparities in pathogen burden in the United States, 1999-2014.

Epidemiology and infection·2019
Same author

The impact of pathogen burden on leukocyte telomere length in the Multi-Ethnic Study of Atherosclerosis.

Epidemiology and infection·2017
Same author

Determination of nicotinic acid and riboflavin in multi-vitamin tablets.

Journal of the American Pharmaceutical Association. American Pharmaceutical Association·2010
Same author

Dietary patterns related to attainment in school: the importance of early eating patterns.

Journal of epidemiology and community health·2008
Same author

Reducing transplant toxicity.

Current opinion in hematology·2001
Same author

Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.

Annals of the New York Academy of Sciences·2001

New, less toxic transplant methods show promise for cancer patients. Minimally myelosuppressive regimens may expand allogeneic hematopoietic cell transplantation options for older or less healthy individuals.

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Conventional allogeneic hematopoietic cell transplantation (HCT) uses myeloablative chemotherapy and radiation, leading to significant toxicity and limiting treatment to younger, healthier patients.
  • T-cell-mediated graft-versus-tumor (GVT) effects are crucial for eliminating malignancy post-HCT.
  • Reducing regimen-related toxicities while preserving GVT effects is a key research objective.

Purpose of the Study:

  • To explore strategies for reducing toxicity in allogeneic HCT.
  • To optimize graft-versus-tumor effects in cancer treatment.
  • To evaluate the potential of less intensive HCT regimens.

Main Methods:

  • Categorizing HCT strategies into reduced-intensity and minimally myelosuppressive regimens.

Related Experiment Videos

  • Investigating regimens that rely on immunosuppression for engraftment and GVT effects.
  • Assessing the feasibility of ambulatory care for certain HCT approaches.

    • Main Results:

    • Preliminary results for minimally myelosuppressive regimens are encouraging.
    • These approaches aim to reduce the morbidity and mortality associated with conventional HCT.
    • The potential for ambulatory care settings is being explored.

    Conclusions:

    • Minimally myelosuppressive HCT regimens show promise in reducing treatment-related toxicity.
    • Successful long-term efficacy could broaden HCT eligibility to a wider patient population.
    • These innovative strategies may offer new hope for patients previously excluded from conventional HCT.